NovoCure (STU:038) Ending Cash Position : €420.8 Mil (As of Mar. 2024)

View and export this data going back to 2017. Start your Free Trial

What is NovoCure Ending Cash Position?

NovoCure's Ending Cash Position for the quarter that ended in Mar. 2024 was €420.8 Mil.

NovoCure's quarterly Ending Cash Position increased from Sep. 2023 (€146.7 Mil) to Dec. 2023 (€222.4 Mil) and increased from Dec. 2023 (€222.4 Mil) to Mar. 2024 (€420.8 Mil).

NovoCure's annual Ending Cash Position declined from Dec. 2021 (€185.5 Mil) to Dec. 2022 (€109.3 Mil) but then increased from Dec. 2022 (€109.3 Mil) to Dec. 2023 (€222.4 Mil).

NovoCure Ending Cash Position Historical Data

The historical data trend for NovoCure's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NovoCure Ending Cash Position Chart

NovoCure Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Ending Cash Position

Get a 7-Day Free Trial

161.47

202.35

185.50

109.35

222.43

NovoCure Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Ending Cash Position	Get a 7-Day Free Trial															174.32	145.37	146.65	222.43	420.77

NovoCure Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

NovoCure's Ending Cash Position for the fiscal year that ended in Dec. 2023 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	106.219	+	116.212
	=	222.4

NovoCure's Ending Cash Position for the quarter that ended in Mar. 2024 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	223.159	+	197.615
	=	420.8

NovoCure Ending Cash Position Related Terms

Thank you for viewing the detailed overview of NovoCure's Ending Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

NovoCure (STU:038) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » NovoCure Ltd (STU:038) » Definitions » Ending Cash Position

Comparable Companies

Traded in Other Exchanges

NVCR:USA

Address

Grenville Street, No. 4 The Forum, Second Floor, St. Helier, JEY, JE2 4UF

Website

https://www.novocure.com

NovoCure Ltd serves in the healthcare sector of the United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Ovarian Cancer, Pancreatic Cancer, Non-Small Cell Lung Cancer, and Brain Metastasis. Products are comprised of two main components: electric field generator and arrays and related accessories. NovoCure derives its major revenues in the United States.

NovoCure (STU:038) Headlines

No Headlines